AEON Biopharma, Inc. AEON
AEON is a biopharmaceutical company advancing its proprietary botulinum toxin complex ABP-450 as a biosimilar to Botox® (onabotulinumtoxinA) with the goal of achieving full-label United States ("U.S.") market entry for debilitating medical conditions.
On December 12, 2022, AEON Biopharma Sub, Inc. (formerly known as AEON Biopharma, Inc.) ("Old AEON") and Priveterra Merger Sub, Inc., a wholly owned subsidiary of Priveterra Acquisition Corp. ("Priveterra"), a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other similar business combination with one or more target businesses, entered into a Business Combination and Merger Agreement (the "Business Combination Agreement" or "BCA") dated December 12, 2022 and amended April 27, 2023.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| R&D | $4.1M | $14.2M | — | $34.8M | — | — |
| SG&A | $12.2M | $13.6M | — | $13.7M | — | — |
| Total operating expenses | $12.8M | -$73.0M | — | $48.4M | — | — |
| Operating income | -$12.8M | $73.0M | — | -$48.4M | -$1.9M | — |
| Pre-tax income | -$39.2M | $42.0M | — | -$52.6M | $8.2M | — |
| Income tax | $0 | $0 | — | $0 | — | — |
| Net income | -$39.2M | $42.0M | — | -$52.6M | $8.2M | — |
| EPS, basic | -3.95 | 77.74 | — | -0.38 | — | — |
| EPS, diluted | -3.95 | 72.93 | — | -0.38 | — | — |
| Shares, diluted (wtd. avg.) | $9.9M | $575.9K | — | $138.8M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $3.0M | $13.0K | $5.2M | $9.7M | $5.1M | — |
| Total current assets | $3.4M | $1.6M | $6.2M | $9.8M | $835.2K | — |
| Property, plant and equipment | $162.0K | $235.0K | $332.0K | $431.0K | — | — |
| Total assets | $5.6M | $3.1M | $6.8M | $10.8M | $276.9M | $81.0K |
| Accounts payable | $942.0K | $5.9M | $3.4M | $7.8M | $634.6K | $21.0K |
| Total current liabilities | $6.9M | $14.1M | $13.0M | $82.6M | $834.6K | $59.6K |
| Total liabilities | $60.6M | $31.7M | $159.9M | $143.2M | $17.9M | $59.6K |
| Retained earnings | -$470.8M | -$431.6M | -$473.6M | -$474.8M | -$17.0M | -$3.6K |
| Total equity | -$55.0M | -$28.6M | -$153.0M | -$270.4M | -$223.8M | $21.4K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$17.3M | -$20.3M | — | -$35.6M | -$1.5M | — |
| Depreciation and amortisation | $78.0K | $97.0K | — | $68.0K | — | — |
| Stock-based compensation | $5.3M | $6.2M | — | $5.9M | — | — |
| Capital expenditure | $4.0K | — | — | $306.0K | — | — |
| Investing cash flow | -$4.0K | — | — | -$306.0K | -$276.0M | — |
| Financing cash flow | $20.3M | $15.1M | — | $40.5M | $278.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001837607-26-000019.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |